{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:23:50Z","timestamp":1787829830239,"version":"build-2784847793"},"reference-count":23,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Onkolojik Bak\u0131\u015f (Oncological Perspective) Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Claudin 18.2 (CLDN18.2) has emerged as a clinically actionable therapeutic target in gastrointestinal malignancies; however, its expression profile and prognostic significance in cholangiocarcinoma (CCA) remain incompletely characterized. This study investigated CLDN18.2 expression in CCA and evaluated its associations with clinicopathological characteristics and overall survival (OS). Methods: This retrospective study included 124 patients with histologically confirmed CCA who were diagnosed between 2010 and 2025. CLDN18.2 expression was assessed by immunohistochemistry using two predefined positivity thresholds (\u226510% and \u226575% of tumor cells showing moderate-to-strong membranous staining). Associations with clinicopathological variables were analyzed, and prognostic significance was evaluated using Kaplan\u2013Meier survival analysis and Firth\u2019s penalized Cox regression. Results: Using a 10% cutoff, CLDN18.2 positivity was detected in 10.5% (13\/124) of cases; using a 75% cutoff, it was detected in 4.8% (6\/124) of cases. At the 75% threshold, CLDN18.2 expression was significantly associated with anatomical location (p = 0.013) and histological subtype (p = 0.002), with the highest positivity observed in perihilar CCA (30.0%) and large-duct intrahepatic CCA (21.7%). The median OS was 9.5 months. CLDN18.2 positivity was not significantly associated with mortality in a univariable Firth\u2019s penalized Cox regression at either the 10% cutoff (hazard ratio (HR) = 1.641, 95% confidence interval (CI): 0.883\u20132.816; p = 0.112) or the 75% cutoff (HR = 1.884, 95% CI: 0.762\u20133.877; p = 0.155). In multivariable Firth\u2019s penalized Cox regression, CLDN18.2 positivity at the 10% cutoff was independently associated with an approximately two-fold increased risk of mortality (HR = 2.072, 95% CI: 1.090\u20133.666; p = 0.028), whereas no independent prognostic significance was observed at the 75% cutoff (HR = 1.906, 95% CI: 0.768\u20133.951; p = 0.150). The absence of adjuvant therapy was independently associated with increased mortality in both models (10% cutoff: HR = 4.870, 95% CI: 1.671\u201313.784; p = 0.004; 75% cutoff: HR = 4.296, 95% CI: 1.521\u201311.899; p = 0.006). Conclusions: CLDN18.2 expression in CCA varies according to anatomical location, histological subtype, and positivity threshold. The relatively high expression observed in perihilar CCA, and large-duct intrahepatic CCA, and the independent prognostic significance identified at the 10% cutoff support the potential role of CLDN18.2 as a prognostic biomarker and therapeutic target in selected patients with CCA. Given the limited sample sizes in some anatomical and histological subgroups, these findings should be interpreted cautiously and validated in larger prospective multicenter studies.<\/jats:p>","DOI":"10.3390\/jcm15176621","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:58:21Z","timestamp":1787828301000},"page":"6621","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Claudin 18.2 Expression in Cholangiocarcinoma: Clinicopathological Heterogeneity, Prognostic Significance, and Impact of Positivity Thresholds"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-0265","authenticated-orcid":false,"given":"Tugba","family":"Toyran","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-8703","authenticated-orcid":false,"given":"Kivilcim","family":"Eren Ates","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat Can","family":"Piskin","sequence":"additional","affiliation":[{"name":"Department of Radiology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"K\u00f6\u015feci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1366-5552","authenticated-orcid":false,"given":"Hatice","family":"Asoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-8569","authenticated-orcid":false,"given":"Yusuf Kemal","family":"Arslan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Topal","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1592-2887","authenticated-orcid":false,"given":"Arbil","family":"Acikalin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","unstructured":"WHO Classification of Tumours Editorial Board (2019). Digestive System Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lauterio, A., De Carlis, R., Centonze, L., Buscemi, V., Incarbone, N., Vella, I., and De Carlis, L. (2021). Current surgical management of peri-hilar and intra-hepatic cholangiocarcinoma. Cancers, 13.","DOI":"10.3390\/cancers13153657"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"154126","DOI":"10.1016\/j.prp.2022.154126","article-title":"Impact of small duct-and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center","volume":"238","author":"Kinzler","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17588359231217967","DOI":"10.1177\/17588359231217967","article-title":"Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer","volume":"16","author":"Kubota","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11523-025-01193-x","article-title":"Claudin-18.2 and Trop-2 as Emerging Biomarkers in Biliary Tract Cancers: Expression Analysis and Therapeutic Potential","volume":"21","author":"Shin","year":"2026","journal-title":"Target. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.21037\/jgo-2024-925","article-title":"Claudin 18 immunohistochemistry in cholangiocarcinoma","volume":"16","author":"Desai","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/liv.16015","article-title":"Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes","volume":"44","author":"Chen","year":"2024","journal-title":"Liver Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/jso.24720","article-title":"Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis","volume":"116","author":"Kim","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1072-7515(01)01016-X","article-title":"Intrahepatic cholangiocarcinoma: Resectability, recurrence pattern, and outcomes","volume":"193","author":"Weber","year":"2001","journal-title":"J. Am. Coll. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3892\/or.2013.2290","article-title":"Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma","volume":"29","author":"Dhanasekaran","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1111\/liv.16047","article-title":"Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence","volume":"44","author":"Salani","year":"2024","journal-title":"Liver Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/cas.70100","article-title":"Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights from MONSTAR-SCREEN-2 Study","volume":"116","author":"Hashimoto","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yu, C., Pan, Y., Li, F., Guo, Z., Xu, D., Zhu, Y., and Yin, B. (2025). Claudin18.2 defines a prognostically distinct subgroup of intrahepatic cholangiocarcinoma via CD8+ T-cell exclusion. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1636367"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/jcp-2023-209268","article-title":"Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts","volume":"78","author":"Yan","year":"2025","journal-title":"J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1158\/1538-7445.AM2023-6482","article-title":"CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: A retrospective analysis","volume":"83","author":"Chong","year":"2023","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14737159.2023.2205588","article-title":"Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features","volume":"23","author":"Chen","year":"2023","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00428-025-04081-x","article-title":"Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma","volume":"486","author":"Kuo","year":"2025","journal-title":"Virchow\u2019s Arch."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"405736","DOI":"10.1200\/JCO.2023.41.36_suppl.405736","article-title":"Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)\/HER2\u2212 locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Primary phase 3 results from GLOW","volume":"41","author":"Xu","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6621\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:14:22Z","timestamp":1787829262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":23,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176621"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176621","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}